Advertisement

Sedative and cardiovascular effects of intranasal or intramuscular dexmedetomidine in healthy dogs

      Abstract

      Objective

      To compare the clinical effects and sedation scores following either intranasal (IN) or intramuscular (IM) administration of dexmedetomidine in dogs.

      Study design

      Prospective, blinded, randomized, clinical study.

      Animals

      A total of 20 client-owned dogs scheduled for noninvasive diagnostic procedures.

      Methods

      Dogs were allocated to be administered dexmedetomidine 0.02 mg kg−1 IN (IN group) or IM (IM group). Sedation was scored before and at 5 minute intervals (for 45 minutes) after drug administration using a composite simple descriptive sedation scale giving a score of 0 (not sedated) to 13 (well sedated). Respiratory frequency (fR), heart rate, haemoglobin oxygen saturation (SpO2) and noninvasive arterial blood pressure were recorded every 5 minutes for 45 minutes. Normally distributed data were analyzed using two-way ANOVA and post hoc Sidak's multiple comparison test. Non-normally distributed data were compared using the Scheier Ray Hare test and post hoc Mann–Whitney U test. Statistical significance was set at p<0.05.

      Results

      Weight, age and sex were not different between groups. Dexmedetomidine onset of action after IN administration was not shorter compared to IM administration (6.3±3.3 versus 9.4±4.6 minutes, p=0.120). Sedation score in the IN group was higher [10 (0–11)] compared to the IM group [6 (0–8)] (p<0.001). At time of peak sedation, heart rate decreased 56% from baseline values in the IM group, and 18% in the IN group. No significant differences in SpO2 and fR were found between the two groups at any time point. No undesirable effects were observed.

      Conclusions and clinical relevance

      Intranasal dexmedetomidine 0.02 mg kg−1 produced effective sedation with less bradycardia and more profound sedation compared to IM administration in healthy dogs and may be considered as an alternative route for dexmedetomidine administration in dogs.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Veterinary Anaesthesia and Analgesia
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Carter J.E.
        • Lewis C.
        • Beths T.
        Onset and quality of sedation after intramuscular administration of dexmedetomidine and hydromorphone in various muscle groups in dogs.
        J Am Vet Med Assoc. 2013; 243: 1569-1572
        • Congdon J.M.
        • Marquez M.
        • Niyom S.
        • Boscan P.
        Evaluation of the sedative and cardiovascular effects of intramuscular administration of dexmedetomidine with and without concurrent atropine administration in dogs.
        J Am Vet Med Assoc. 2011; 239: 81-89
        • Dale O.
        • Hjortkaer R.
        • Kharasch E.D.
        Nasal administration of opioids for pain management in adults.
        Acta Anaesthesiol Scand. 2002; 46: 759-770
        • Graff C.L.
        • Pollack G.M.
        Nasal drug administration: potential for targeted central nervous system delivery.
        J Pharm Sci. 2005; 94: 1187-1195
        • Granholm M.
        • McKusick B.C.
        • Westerholm F.C.
        • Aspegrén J.C.
        Evaluation of the clinical efficacy and safety of intramuscular and intravenous doses of dexmedetomidine and medetomidine in dogs and their reversal with atipamezole.
        Vet Rec. 2007; 160: 891-897
        • Grassin-Delyle S.
        • Buenestado A.
        • Naline E.
        • et al.
        Intranasal drug delivery: an efficient and non-invasive route for systemic administration: focus on opioids.
        Pharmacol Ther. 2012; 134: 366-379
        • Gurney M.
        • Cripps P.
        • Mosing M.
        Subcutaneous pre-anaesthetic medication with acepromazine-buprenorphine is effective as and less painful than the intramuscular route.
        J Small Anim Pract. 2009; 50: 474-477
        • Han G.
        • Yu W.W.
        • Zhao P.
        A randomized study of intranasal vs. intravenous infusion of dexmedetomidine in gastroscopy.
        Int J Clin Pharmacol Ther. 2014; 52: 756-761
        • Hornak S.
        • Liptak T.
        • Ledecky V.
        • et al.
        A preliminary trial of the sedation induced by intranasal administration of midazolam alone or in combination with dexmedetomidine and reversal by atipamezole for a short-term immobilization in pigeons.
        Vet Anaesth Analg. 2014; 42: 192-196
        • Iirola T.
        • Vilo S.
        • Manner T.
        • et al.
        Bioavailability of dexmedetomidine after intranasal administration.
        Eur J Clin Pharmacol. 2011; 67: 825-831
        • Illum L.
        Transport of drugs from the nasal cavity to the central nervous system.
        Eur J Pharm Sci. 2000; 11: 1-18
        • Jayaraman L.
        • Sinha A.
        • Punhani D.
        A comparative study to evaluate the effect of intranasal dexmedetomidine versus oral alprazolam as a premedication agent in morbidly obese patients undergoing bariatric surgery.
        J Anesthesiol Clin Pharmacol. 2013; 29: 179-182
        • Johnson N.J.
        • Hanson L.R.
        • Frey W.H.
        Trigeminal pathways deliver a low molecular weight drug from the nose to the brain and orofacial structures.
        Mol Pharm. 2010; 7: 884-893
        • Kozlovskaya L.
        • Abou-Kaoud M.
        • Stepensky D.
        Quantitative analysis of drug delivery to the brain via nasal route.
        J Control Release. 2014; 189: 133-140
        • Musulin S.E.
        • Mariani C.L.
        • Papich M.G.
        Diazepam pharmacokinetics after nasal drop and atomized nasal administration in dogs.
        J Vet Pharmacol Ther. 2010; 34: 17-24
        • Pardeshi C.V.
        • Belgamwar V.S.
        Direct nose to brain drug delivery via integrated nerve pathways bypassing the blood-brain barrier: an excellent platform for brain targeting.
        Expert Opin Drug Deliv. 2013; 10: 957-972
        • Pascoe P.J.
        The cardiopulmonary effects of dexmedetomidine infusions in dogs during isoflurane anesthesia.
        Vet Anaesth Analg. 2014; 42: 360-368
        • Santangelo B.
        • Micieli F.
        • Mozzillo T.
        • et al.
        Transnasal administration of a combination of dexmedetomidine, midazolam and butorphanol produces deep sedation in New Zealand white rabbits.
        Vet Anaesth Analg. 2016; 43: 209-214
        • Schnellbacher R.W.
        • Hernandez S.M.
        • Tuberville T.D.
        • et al.
        The efficacy of intranasal administration of dexmedetomidine and ketamine to yellow-bellied sliders (Trachemys scripta scripta).
        J Herpetol Med Surg. 2012; 22: 91-98
        • Stevens J.
        • Ploeger B.A.
        • van der Graaf P.H.
        • et al.
        Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration.
        Drug Metab Dispos. 2011; 39: 2275-2282
        • Yuen V.M.
        • Irwin M.G.
        • Hui T.W.
        • et al.
        A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine.
        Anesth Analg. 2007; 105: 374-380